Zacks Small-Cap Research

Our model applies a 15% probability of ultimate approval and commercialization for RXI-109 and Samcyprone. The model includes contributions from the US, EU and rest of world. exercise price of $0.70. Zacks Investment Research Page 2 scr.zacks.com WHATS NEW On October 3rd, 2018 RXi Pharmaceuticals Corp. (NASDAQ: RXII) ... ................
................